Intellectual property should not be an obstacle to a fair distribution of vaccines.

Spain Pedro Sánchez · Prime Minister of Spain

13 May 2021

Context
Sánchez published an op-ed in May 2021 urging global leaders to suspend COVID-19 vaccine patent protections and scale up equitable vaccine distribution worldwide.
Main themes
Global vaccine equity, intellectual property and TRIPS waiver, COVID-19 pandemic response, vaccine production and supply, technology transfer, COVAX and multilateral cooperation, trade barriers removal, pharmaceutical innovation vs. public health, mRNA vaccine manufacturing, G-20 and WHO frameworks
Duration
~6 min
20th percentile
Words
724
20th percentile
Sentences
39
24th percentile
Readability
42
40th percentile
Grade
12.0
45th percentile
Syntax
2.84
26th percentile
Vocabulary
2.22
54th percentile

Translated from Spanish

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 41%41%
  • Social 38%38%
  • Geopolitical 10%10%
  • Institutional 10%10%
  • Technological 0%0%
  • Environmental 0%0%
  • Ceremonial 0%0%
  • Not in focus 0%

39 sentences in 12 paragraphs

Covid-19 has profoundly affected the world. But while we mourn the millions of victims, we can already see the light at the end of the tunnel thanks to the acceleration of vaccination campaigns. Humanity has never before developed safe and effective vaccines against a new disease in such a short period of time. Scientific progress has brought us hope.

But this sense of hope does not reach everyone equally. We are still far from the goal of ensuring fair and affordable access to vaccines worldwide. The virus continues to spread uncontrollably in several countries and regions, increasing the risk of new dangerous mutations occurring.

No one will be safe until everyone is safe. It is not just a matter of justice — it is key to combating the pandemic efficiently and effectively.

By the end of May, 2 billion doses of the Covid vaccine will have been produced worldwide. But we need around 11 billion doses to immunize 70% of the global population. Meanwhile, COVAX, the World Health Organization's vaccine procurement program, will only supply 145 million doses by the end of June, 100 million fewer than initially planned. Vaccine production and access must increase exponentially and urgently.

The debate on how to ensure this happens remains polarized. The costs of pharmaceutical innovation are very high, while the costs of imitation are relatively low. The development of medicines takes an average of 10 years and requires an investment of 2.5 billion dollars (2 billion euros). In normal times, patents play a key role in fostering innovation. But we are not in normal times.

We find ourselves in the midst of a serious pandemic, and we must use all means at our disposal to end it as soon as possible. In this context, intellectual property cannot be an obstacle to ensuring equitable and universal access to vaccines. This is why an urgent consensus must be sought, as some countries have urged, on the United States' proposal to temporarily suspend certain obligations under the TRIPS intellectual property agreement for Covid vaccines. Furthermore, in light of future health emergencies, we should seek to adapt global rules on intellectual property rights.

However, intellectual property rights are only part of the equation. There are around 80 patents involved in the creation of an mRNA vaccine, whose production encompasses 280 distinct components sourced from 86 suppliers in 19 countries, and whose storage and distribution require very complex logistics.

This is why Spain proposes a comprehensive initiative to facilitate the transfer of the necessary technology and expertise, lift all barriers to increase production, and accelerate the distribution of the vaccine.

First, until an agreement is reached at the World Trade Organization, we must use all available mechanisms to encourage pharmaceutical companies to engage in voluntary licensing agreements and share all knowledge related to the virus, including through the WHO's Covid-19 Technology Access Pool initiative. The upcoming G-20 global health summit and the World Health Assembly should be leveraged to encourage the industry to transfer the necessary knowledge.

Second, it is essential to make full use of existing industrial capacities while simultaneously removing trade barriers and ensuring the proper functioning of supply chains. We must avoid the existence of underutilized resources and quickly identify surpluses and deficits of essential goods, helping to optimize the distribution of supplies. Specific and urgent measures must also be implemented to facilitate trade. All countries should commit to relaxing or eliminating trade barriers, including import tariffs and export bans that exist throughout the industrial value chain, so that they cover finished vaccines and the raw materials and components needed to produce them.

Third, the transportation, distribution, and delivery of vaccines must be accelerated, both between countries and within them. COVAX must receive the financial and non-financial assistance it needs to meet the goal of supplying at least 2 billion doses by the end of the year. Additionally, the pillar that constitutes the "connector of health systems" of the WHO's global collaborative framework should be strengthened to build the necessary processing, storage, distribution, and delivery capacity.

The supply of vaccines for all is the first step towards a better reconstruction. Scientific progress has given us the necessary tools to control the deadliest pandemic in generations. Now, both governments and the private sector must rise to the challenge. We all must do our part. There is no other alternative.